DJIA 17,730.11 -27.80 -0.16%
NASDAQ 5,009.21 0.00 0.00%
S&P 500 2,076.78 -0.64 -0.03%
market minute promo

Rexahn Pharmaceuticals (NYSEMKT: RNN)

0.61 -0.01 (-0.98%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RNN $0.61 -0.98%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.62
Previous Close $0.61
Daily Range $0.61 - $0.64
52-Week Range $0.60 - $0.96
Market Cap $108.6M
P/E Ratio -15.13
Dividend (Yield) $0.00 (0.0%)
Volume 283,847
Average Daily Volume 701,228
Current FY EPS -$0.12

Sector

Healthcare

Industry

Drug Makers

Rexahn Pharmaceuticals (RNN) Description

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Website: http://www.rexahn.com/

News & Commentary Rss Feed

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo

Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of

Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for C

Rexahn Pharmaceuticals to Present Data on RX-3117 & Supinoxin at the 2015 American Association for Cancer Research Annual Meeting

Rexahn Pharmaceuticals: One Biotech To Buy For A Catalyst-Filled 2015

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Fl

UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility

Onxeo: An Upcoming Mid-Sized Pharma With Ambitions

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 12.5% - Tale of the Tape

Can The Uptrend Continue for Rexahn Pharmaceuticals (RNN)? - Tale of the Tape

Update: Rexahn Likens Partnership With Demonstrated Potential Of RX-3117

Why Rexahn Pharmaceuticals (RNN) Could Be Positioned for a Surge? - Tale of the Tape

See More RNN News...

RNN's Top Competitors

RNN $0.61 (-0.98%)
Current stock: RNN
AMGN $153.26 (-1.12%)
Current stock: AMGN
GILD $115.04 (-0.84%)
Current stock: GILD
BIIB $404.28 (-0.28%)
Current stock: BIIB